AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%
Last update at 2024-04-25T20:10:00Z
Breakdown | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 | 2019-04-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 | 2019-04-30 |
Income before tax | 5364.00M | 5517.00M | 3895.00M | 4055.00M | 5197.00M |
Minority interest | -26.00000M | -22.00000M | 174.00M | 17.00M | 121.00M |
Net income | 3758.00M | 5039.00M | 3606.00M | 4789.00M | 4631.00M |
Selling general administrative | 10415.00M | 10292.00M | 10148.00M | 9875.00M | 10232.00M |
Selling and marketing expenses | - | - | - | - | - |
Gross profit | 20508.00M | 21541.00M | 19634.00M | 19489.00M | 21402.00M |
Reconciled depreciation | 2697.00M | 2707.00M | 2702.00M | 2663.00M | 2659.00M |
Ebit | 5485.00M | 5752.00M | 4484.00M | 4791.00M | 7005.00M |
Ebitda | 9042.00M | 8932.00M | 7933.00M | 8241.00M | 9664.00M |
Depreciation and amortization | 3557.00M | 3180.00M | 3449.00M | 3450.00M | 2659.00M |
Non operating income net other | 515.00M | 318.00M | 336.00M | 356.00M | 373.00M |
Operating income | 5485.00M | 5752.00M | 4484.00M | 4791.00M | 6268.00M |
Other operating expenses | 25397.00M | 25778.00M | 25222.00M | 23691.00M | 23925.00M |
Interest expense | 636.00M | 553.00M | 925.00M | 1092.00M | 1444.00M |
Tax provision | 1580.00M | 456.00M | 265.00M | -751.00000M | 547.00M |
Interest income | 164.00M | 541.00M | 617.00M | 379.00M | 676.00M |
Net interest income | -636.00000M | -553.00000M | -925.00000M | -1092.00000M | -1444.00000M |
Extraordinary items | - | - | 106.00M | 63.00M | -12.00000M |
Non recurring | -30.00000M | 95.00M | 118.00M | 313.00M | 166.00M |
Other items | - | - | - | - | 0.00000M |
Income tax expense | 1580.00M | 456.00M | 265.00M | -751.00000M | 547.00M |
Total revenue | 31227.00M | 31686.00M | 30117.00M | 28913.00M | 30557.00M |
Total operating expenses | 14678.00M | 15633.00M | 14739.00M | 14267.00M | 14770.00M |
Cost of revenue | 10719.00M | 10145.00M | 10483.00M | 9424.00M | 9155.00M |
Total other income expense net | -121.00000M | -235.00000M | -589.00000M | -736.00000M | 9.00M |
Discontinued operations | - | - | - | - | 0.00000M |
Net income from continuing ops | 3784.00M | 5062.00M | 3630.00M | 4806.00M | 4650.00M |
Net income applicable to common shares | 3758.00M | 5039.00M | 3606.00M | 4789.00M | 4631.00M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 | 2019-04-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 | 2019-04-30 |
Total assets | 90948.00M | 90981.00M | 93083.00M | 90689.00M | 89694.00M |
Intangible assets | 14844.00M | 15595.00M | 17740.00M | 19063.00M | 20560.00M |
Earning assets | - | - | - | - | - |
Other current assets | 2425.00M | 2319.00M | 1956.00M | 2209.00M | 2144.00M |
Total liab | 39283.00M | 38259.00M | 41481.00M | 39817.00M | 39482.00M |
Total stockholder equity | 51483.00M | 52551.00M | 51428.00M | 50737.00M | 50091.00M |
Deferred long term liab | 708.00M | 884.00M | 1028.00M | 1174.00M | 1278.00M |
Other current liab | 6369.00M | 6376.00M | 6392.00M | 5594.00M | 5681.00M |
Common stock | 0.13M | 0.13M | 0.13M | 0.13M | 0.13M |
Capital stock | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
Retained earnings | 30392.00M | 30250.00M | 28594.00M | 28132.00M | 26270.00M |
Other liab | 6771.00M | 5493.00M | 5765.00M | 6656.00M | 6524.00M |
Good will | 41425.00M | 40502.00M | 41961.00M | 39841.00M | 39959.00M |
Other assets | -1.00000M | 1.00M | 1.00M | 3486.00M | 2108.00M |
Cash | 1543.00M | 3714.00M | 3593.00M | 4140.00M | 4393.00M |
Cash and equivalents | 1543.00M | 3714.00M | 3593.00M | 4140.00M | 4393.00M |
Total current liabilities | 9051.00M | 12394.00M | 8509.00M | 10366.00M | 8472.00M |
Current deferred revenue | - | - | - | - | 315.00M |
Net debt | 22821.00M | 20400.00M | 22796.00M | 20657.00M | 20931.00M |
Short term debt | 20.00M | 3742.00M | 11.00M | 2776.00M | 838.00M |
Short long term debt | 20.00M | 3742.00M | 11.00M | 2771.00M | 832.00M |
Short long term debt total | 24364.00M | 24114.00M | 26389.00M | 24797.00M | 25324.00M |
Other stockholder equity | 24590.00M | 24566.00M | 26319.00M | 26165.00M | 26532.00M |
Property plant equipment | 6610.00M | 5413.00M | 6219.00M | 4828.00M | 4675.00M |
Total current assets | 21675.00M | 23059.00M | 22548.00M | 22031.00M | 21967.00M |
Long term investments | - | - | - | - | 416.00M |
Net tangible assets | 51483.00M | -3546.00000M | -8273.00000M | 50737.00M | -10428.00000M |
Short term investments | 6416.00M | 6859.00M | 7224.00M | 6808.00M | 5455.00M |
Net receivables | 5998.00M | 5551.00M | 5462.00M | 4645.00M | 6222.00M |
Long term debt | 24344.00M | 20372.00M | 26378.00M | 21976.00M | 24476.00M |
Inventory | 5293.00M | 4616.00M | 4313.00M | 4229.00M | 3753.00M |
Accounts payable | 2662.00M | 2276.00M | 2106.00M | 1996.00M | 1953.00M |
Total permanent equity | - | - | - | - | 0.00000M |
Noncontrolling interest in consolidated entity | 182.00M | 171.00M | 174.00M | 135.00M | 121.00M |
Temporary equity redeemable noncontrolling interests | - | - | - | - | 0.00000M |
Accumulated other comprehensive income | -3499.00000M | -2265.00000M | -3485.00000M | -3560.00000M | -2711.00000M |
Additional paid in capital | - | - | - | - | 0.00000M |
Common stock total equity | - | - | - | - | 0.00000M |
Preferred stock total equity | - | - | - | - | 0.00000M |
Retained earnings total equity | 30392.00M | 30250.00M | 28594.00M | 28132.00M | 26270.00M |
Treasury stock | - | - | - | - | 0.00000M |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 7436.00M | 6411.00M | 5612.00M | 4926.00M | 2533.00M |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 69274.00M | 67921.00M | 70534.00M | 68658.00M | 67727.00M |
Capital lease obligations | 64.00M | 62.00M | 71.00M | 50.00M | 16.00M |
Long term debt total | 24344.00M | 20372.00M | 26378.00M | 22021.00M | 24486.00M |
Breakdown | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 | 2019-04-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 | 2019-04-30 |
Investments | -3493.00000M | -190.00000M | -463.00000M | -1465.00000M | 2532.00M |
Change to liabilities | 696.00M | 213.00M | 531.00M | -44.00000M | 399.00M |
Total cashflows from investing activities | -3493.00000M | -1659.00000M | -2866.00000M | -3203.00000M | -774.00000M |
Net borrowings | -598.00000M | -1.00000M | -570.00000M | -559.00000M | -713.00000M |
Total cash from financing activities | -4960.00000M | -5336.00000M | -4136.00000M | -4198.00000M | -5431.00000M |
Change to operating activities | - | -65.00000M | -549.00000M | -609.00000M | -624.00000M |
Net income | 3784.00M | 5062.00M | 3630.00M | 4806.00M | 4650.00M |
Change in cash | -2171.00000M | 121.00M | -547.00000M | -253.00000M | 724.00M |
Begin period cash flow | 3714.00M | 3593.00M | 4140.00M | 4393.00M | 3669.00M |
End period cash flow | 1543.00M | 3714.00M | 3593.00M | 4140.00M | 4393.00M |
Total cash from operating activities | 6039.00M | 7346.00M | 6240.00M | 7234.00M | 7007.00M |
Issuance of capital stock | 308.00M | 429.00M | 474.00M | 662.00M | 992.00M |
Depreciation | 2697.00M | 2707.00M | 2702.00M | 2663.00M | 2659.00M |
Other cashflows from investing activities | -1863.00000M | -10.00000M | -54.00000M | -525.00000M | 1827.00M |
Dividends paid | -3616.00000M | -3383.00000M | -3121.00000M | -2894.00000M | 2693.00M |
Change to inventory | -939.00000M | -560.00000M | 78.00M | -577.00000M | -274.00000M |
Change to account receivables | -576.00000M | -477.00000M | -761.00000M | 1291.00M | -581.00000M |
Sale purchase of stock | -645.00000M | -2544.00000M | -652.00000M | -1326.00000M | -2877.00000M |
Other cashflows from financing activities | 7284.00M | 163.00M | 9694.00M | 5470.00M | 7095.00M |
Change to netincome | 525.00M | 489.00M | 633.00M | -296.00000M | 778.00M |
Capital expenditures | 1459.00M | 1368.00M | 1355.00M | 1213.00M | 1134.00M |
Change receivables | -576.00000M | -477.00000M | -761.00000M | 1291.00M | -581.00000M |
Cash flows other operating | -148.00000M | -65.00000M | -549.00000M | -609.00000M | -624.00000M |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | -2414.00000M | 351.00M | -762.00000M | -167.00000M | 802.00M |
Change in working capital | -967.00000M | -889.00000M | -701.00000M | 61.00M | -1080.00000M |
Stock based compensation | 355.00M | 359.00M | 344.00M | 297.00M | 290.00M |
Other non cash items | 396.00M | 711.00M | 687.00M | 722.00M | 792.00M |
Free cash flow | 4580.00M | 5978.00M | 4885.00M | 6021.00M | 5873.00M |
Sector: Healthcare Industry: Medical Devices
Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
MDT Medtronic PLC |
-1.13 1.41% | 79.25 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
ABT Abbott Laboratories |
-0.03 0.03% | 106.86 | 37.15 | 23.15 | 4.67 | 4.97 | 4.88 | 19.38 |
SYK Stryker Corporation |
0.30 0.09% | 337.15 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
BSX Boston Scientific Corp |
0.35 0.48% | 73.26 | 68.17 | 24.57 | 5.85 | 4.26 | 6.46 | 26.80 |
SEMHF Siemens Healthineers AG |
- -% | 53.36 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
20 On Hatch, Dublin, Ireland, 2
Name | Title | Year Born |
---|---|---|
Mr. Geoffrey Straub Martha | Chairman & CEO | 1970 |
Ms. Karen L. Parkhill | EVP, CFO, IT & Enterprise Excellence | 1965 |
Mr. Ivan K. Fong | Exec. VP, Gen. Counsel & Sec. | 1961 |
Mr. Robert J. W. ten Hoedt | Exec. VP & Pres of Global Regions | 1960 |
Mr. Robert John White | Exec. VP & Pres of Medical Surgical Portfolio | 1963 |
Mr. Mark Ploof | Sr. VP of Global Operations and Bus. Services | NA |
Ms. Jennifer M. Kirk | Principal Accounting Officer, Global Controller & Chief Accounting Officer | 1975 |
Dr. Laura Mauri M.D., M.Sc. | Sr. VP and Chief Scientific, Medical & Regulatory Officer | NA |
Mr. Sean Lennon | Chief Information Officer | NA |
Mr. Ryan Weispfenning | VP of Investor Relations | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).